NorthWest Biotherapeutics Inc (NWBO)

[jm100]

1 Expected to be approved for marketing-a new diagnosis of glioma DCVax-L vaccine

On May 29, 2018, Northwest Biology disclosed the phase III interim data of its personalized autologous dendritic cell vaccine DCVax-L: a personalized glioblastoma vaccine may prolong the long-term survival of some patients . The vaccine, called DCVax- L, uses the patient's own dendritic cells to help activate the immune system to fight cancer.

Nearly 30% of the patients in the trial have survived for at least three years since they were enrolled in the clinic (the patients will continue to be followed up). It is worth mentioning that this study is by far the largest clinical trial of a customized vaccine in patients diagnosed with fatal brain cancer.

Between July 2007 and November 2015, the vaccine was administered to newly diagnosed glioblastoma patients in 80 locations around the world , and all patients received standard treatment (surgical removal of the tumor, followed by surgery) before participating in the trial. Chemotherapy).

Due to the crossover design of the trial, nearly 90% of the patients received the vaccine treatment in the end.

The interim trial data of the previously announced phase III clinical study. Of the patients enrolled in the clinic for more than three years, 67 patients (30% ) survived more than 30 months, and 44 patients (24.2%) survived more than 36 months . The median survival time of these patients is estimated to be 46.5 to 88.2 months. At the time of analysis, 108 (32.6%) of the 331 patients who participated in the trial were still alive.

So far, the clinical trial of DCVax-L has been conducted for 12 years, which is extraordinary. The first patient was enrolled 12 years ago, and the last patient was enrolled 5 years ago. Everyone is looking forward to the final data of this therapy, and also looking forward to its approval as the first immunotherapy for brain tumors as soon as possible!

2 The progression-free survival is increased by 50%, and the AV-GBM-1 vaccine brings new hope to patients with brain tumors